Overview

Psilocybin for Treatment of Obsessive Compulsive Disorder

Status:
Active, not recruiting
Trial end date:
2022-12-01
Target enrollment:
0
Participant gender:
All
Summary
This study will evaluate whether psilocybin, a hallucinogenic drug, improves symptoms of obsessive compulsive disorder (OCD), whether it is safely tolerated as treatment of OCD, and will investigate the mechanisms by which it works.
Phase:
Phase 1
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
University of Arizona
Treatments:
Lorazepam
Psilocybin
Psilocybine
Criteria
Inclusion Criteria:

- Have moderate to severe OCD (DSM-5) after diagnostic interview using the Structured
Clinical Interview for DSM-5 Research Version (SCID-R).

- Failed at least one adequate attempted routine care treatment.

- Considered safe for independent living

Exclusion Criteria:

- Concurrent psychosis, active substance use disorder, or a personal history of
psychosis.

- Medical illness based on physical examination and routine blood testing that may
complicate cardiovascular safety or drug metabolism or excretion, such as uncontrolled
hypertension, severe cardiac disease, or kidney or liver failure.

- Unstable Chronic Obstructive Pulmonary Disease (COPD) or severe sleep apnea

- Psychiatric comorbidity that may represent an acute risk to their own or others'
safety.

- Subjects may not be using antidepressant medication for OCD for at least two weeks
before receiving study drug, and they cannot require any sedative, narcotic, or
neuroleptic medications on a regular basis. Any of these medications they have taken
should have been stopped long enough in the past to allow for their elimination and
safe withdrawal prior to starting administration of the study drug. The specific time
required will be dependent on the medication the patient was previously receiving.

- Women who are pregnant, breastfeeding, or unwilling/unable to practice medically
acceptable birth control during the study.

- Allergy to lorazepam.